MVM closes fourth fund at $233M

MVM Life Science Partners closed its fourth fund, MVM IV, at $233 million. The firm said it will invest $15-$30 million per company in healthcare companies of all stages in the U.S. and Europe.

MVM invests in therapeutics, medical device companies and healthcare IT plays. It has invested in pain company Cara Therapeutics Inc. (NASDAQ:CARA), osteoporosis company Tarsa Therapeutics Inc. (Philadelphia, Pa.) and bioTheranostics Inc. (San Diego, Calif.), which develops molecular-based cancer tests. ...